PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Adjuvant Therapy After Neoadjuvant Immunochemotherapy Improves Survival in Resected ESCC

esophageal squamous cell carcinomaneoadjuvant immunochemotherapyadjuvant chemotherapyadjuvant chemoimmunotherapyimmune checkpoint inhibitorstislelizumabpembrolizumabsintilimabcamrelizumabtoripalimabreal-world studypropensity score matchingoverall survivaldisease-free survival Oncology Pharmacy

Background Information

Postoperative adjuvant therapy enhances survival for ESCC after neoadjuvant treatment.

Identifying the best postoperative adjuvant therapy for esophageal squamous cell carcinoma (ESCC) after neoadjuvant immunochemotherapy (nICT) is crucial for improving patient outcomes. Postoperative adjuvant chemotherapy (POCT) and chemoimmunotherapy (POICT) both improved overall survival (OS) and disease-free survival (DFS) compared to observation. In non-pathological complete response (non-pCR) patients, both methods were effective, but only POICT helped pathological complete response (pCR) patients. This study highlights that while adding immunotherapy to chemotherapy (POICT) does not significantly extend survival in all matched patients, it may benefit pCR patients specifically. For ESCC patients post-nICT, adjuvant therapy improves survival; POICT may benefit pCR patients more.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Zhang X, Gao H, Cao J, Gao M, Xu Y, Zhang W, Qian P, Liu X, Fu Z, Shen W

Citation: Zhang X, Gao H, Cao J, et al. A real-world multicenter study on postoperative adjuvant treatment patterns and prognostic implications following neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. Frontiers in immunology. 2026;17:1811836. doi:10.3389/fimmu.2026.1811836

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.